Hematological malignancies
Conditions
Sponsors
Sapporo Hokuyu Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with refractory or relapsed hematological malignancies 2. Performance Status; 0-2 3. Survival period is expected more than 4 months 4. HLA-A*2402, 0201 or 0206 positive 5. Meet the following criteria for organ functions 1) WBC more than 2,500/microliter, Hemoglobin more than 9.0 g/dl, Platelet more than 90,000/microliter 2) Serum AST/ALT less than 2.5 folds of the upper normal limit 3) Serum bilirubin less than1.5 folds of the upper normal limit 4) Serum Albumin more than 3.0g/dl 5) Serum creatinine within normal limitation 6) No serious ECG abnormality 6. Patients can tolerate blood component collection (apheresis) to collect peripheral blood mononuclear cells. 7. Informed consent has been obtained.
Exclusion criteria
Exclusion criteria: 1. There is deep-seated active infection. 2. There are severe complications including malignant hypertension, cardiac failure, liver cirrhosis, severe DM, severe lung disease, active interstitial pneumonitis. 3. Patients who have complications are considered inappropriate for the trial. 4. There are other malignancies. 5. Pregnant or lactating woman. 6. Past history of severe drug allergy. 7. There is severe psychiatric disease. 8. The patient is considered inappropriate for the trial by a responsible doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events, Immunological response, Efficacy | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival, Overall survival | — |
Countries
Japan
Contacts
Public ContactIkumi Yamada
Sapporo Hokuyu Hospital Cellular Immunotherapy Center
Outcome results
None listed